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OBJECTIVES: To identify what was the influence of cardiovascular drugs 
recommendations issued by AOTM in years 2005-2012 for the reimbursement 
decisions taken by Minister of Health (MoH). The main task of AOTM, established 
in 2005, is to prepare recommendations on financing all medical technologies 
from public funds for the MoH. For all new health technologies entering market 
full pharmacoeconomic evaluations are required before the reimbursement 
decisions are taken by MoH METHODS: Among recommendations of AOTM 
published until the end of 2012 we analyzed all related to cardiovascular drugs. 
The recommendations were identified and categorized into types of 
recommendations (positive or negative). We compared the outcomes with 
reimbursement list officially published by MoH (January 2013). RESULTS: Among 
753 documents (recommendations, opinions, statements) issued by AOTM, only 
38 (5%) applied to innovative, cardiovascular drugs. AOTM issued positive 
recommendations for reimbursement to 22 of 38 of cardiovascular drug 
submissions (58%). 16 of 38 (42%) were not approved and received negative 
recommendations. Having analyzed the reimbursement list we realized that only 
10 of 38 (26%) drugs assessed by AOTM are occurred on the reimbursement list. 9 
of 10 drugs(90%) were positive recommended by AOTM. Only 1 drug (10%) was 
assessed negative. CONCLUSIONS: The influence of recommendations issued by 
AOTM for cardiovascular drugs for reimbursement decisions taken by MOH were 
not significant with respect to place the drugs on the list. But we can realize that 
only 1 drug with negative AOTM recommendation exists on the list. The 
conclusion indicates that the medicine with negative recommendations probably 
will not be accepted (in 90%) for reimbursement from public sources. Contrarily, 
not every drug with positive recommendation issued by AOTM will be placed on 
the reimbursement list.  
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OBJECTIVES: This study was performed to evaluate and provide a new positive  
list of antihypertensive drugs for reimbursement in the Korean national health 
insurance. METHODS: First, among total 1,226 items, 360 combination items were 
excluded from this evaluation and 25 essential drug items (ban-on-delisting drugs, 
orphan drugs, emergency drugs, and drugs without any alternatives) were to 
remain on reimbursement list without any evaluation. Next, clinical usefulness was 
evaluated by criteria from medical textbooks, guidelines, and WHO lists, and 1 item 
was to be delisted due to lack of clinical usefulness. In the third step, daily cost  
was calculated. Drugs which belong to bottom 25% in daily cost were defined as 
“relatively low-price drugs,” which could remain on the list without subsequent 
evaluation. Other drugs were to be evaluated by cost-effectiveness. Clinical 
effectiveness was evaluated based on proxy outcomes (blood pressure) and final 
outcomes (mortality, morbidity) by reviewing clinical literatures and 6 assessment 
reports from overseas health technology institutions as well as opinions of clinical 
experts. RESULTS: There was no clear evidence depicting differences in clinical 
effectiveness. Therefore, the prices of hypertension drugs would have to be reduced 
to the lowest level of all hypertension drugs if a cost-minimization principle  
is applied. However, the lowest levels within each class were suggested instead in 
recognition of differences in adverse events and effects on co-morbidity among  
the classes. CONCLUSIONS: It was not proven that a particular class or ingredient 
among hypertensive drugs was superior to others. However, the policy based  
on this result has to be carefully implemented. It is important that practicability, 
fairness, and equity of the result as well as scientific accuracy have to be  
balanced since this type of study is commonly associated with interests of 
stakeholders.  
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OBJECTIVES: To investigate whether or not elimination of decision uncertainty 
related to the new anticoagulants would be cost-effective, by calculating the 
added value of conducting an RCT comparing the new oral anticoagulants 
(apixaban, dabigatran and rivaroxaban) relative to each other and relative to 
warfarin for stroke prevention in patients with atrial fibrillation. METHODS: We 
developed a decision analytic model, designed as a probabilistic Markov model 
containing 200 different probability distributions. The model included eight 
health states; atrial fibrillation (AF), heart failure, moderate stroke sequela, 
severe stroke sequela, atrial fibrillation with previous acute myocardial 
infarction (AMI), atrial fibrillation with previous stroke, major gastrointestinal 
bleeding and dead. Epidemiological input data was gathered from registries. Data 
on Quality of Life were based on published EQ-5D data and costs were based on 
national tariffs. Efficacy data included the three major randomised controlled 
trials comparing each of the new oral anticoagulants (apixaban, dabigatran and 
rivaroxaban) to warfarin. Current efficacy estimates indicate that the new 
anticoagulants are efficacious on some, but not all, outcomes compared to 
warfarin. However, no direct evidence comparing any of these new 
anticoagulants with each other is yet available. RESULTS: Expected value of 
perfect information analysis on groups of parameters (EVPPI) for efficacy 
parameters was clearly much higher than EVPPI for other parameters (QALYs, 
costs and baseline risk epidemiological data). Population EVPPI for efficacy data 
was $ 1.3 billion in a population of 5 million, given an assumed threshold value 
of $ 100,000 per QALY gained. CONCLUSIONS: There is clearly an added value in 
conducting more research on the efficacy of new oral anticoagulants. Hence, 
new randomized controlled trial(s) comparing all of the new oral anticoagulants 
would probably decrease decision uncertainty considerably.  
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OBJECTIVES: To examine the demographic and clinical characteristics,  
and cardiovascular treatment in patients with high-risk vascular disease (HRVD). 
METHODS: A large employer-based US administrative claims database was used 
to conduct this retrospective cohort study. Patients with HRVD (defined  
as cerebrovascular disease [CVD], coronary artery disease with diabetes [CADD], 
peripheral artery disease [PAD], or history of acute coronary syndrome [ACS] 
[≥30days through 365 days after discharge for ACS]) between October 1, 2008  
to September 30, 2009, ≥65 years of age, were identified with minimum 12-month 
pre- and 24-month post-index health plan eligibility. Patients’ baseline 
demographic characteristics, comorbidities, and medication use were examined 
and compared across groups with and without polyvascular disease. RESULTS: 
There were 525,893 HRVD patients identified with an average age of 77.2  
years and gender of 51.0% male. Of the identified patients, 59.5% had 
hypertension, 32.9% had hypercholesterolemia, and 44.7% had diabetes. Patients 
were generally undertreated with statins (50.3% HRVD; range: 44.9% PAD to 
64.0% CADD), antiplatelets (21.4% HRVD; range: 16.8% CVD to 49.7% ACS), beta-
blockers (41.8% HRVD; range: 35.2% CVD to 67.1% ACS), and other evidence-based 
risk reduction therapies. Patients with >1 affected artery bed (18%) had 
numerically similar age (age: 77.1, 77.6, 77.0 for 1, 2, 3 affected disease beds), but 
had higher cardiovascular risk factors (for 1, 2, 3 affected disease beds, 
hypertension: 57.2%, 69.1%, 73.4%; hypercholesterolemia: 32.0%, 36.6%, 37.3%; 
diabetes: 40.5%, 61.2%, 83.9%), and used more cardiovascular-related 
medications (statins: 48.0%, 59.9%, 67.5%; antiplatelets: 18.3%, 33.8%, 48.8%; beta-
blockers: 39.0%, 53.3%, 64.4%) compared to patients with only 1 affected disease 
bed (p<0.01). The average number of medications per patient was 9.1 for HRVD 
patients, ranging from 7.6 for CVD-alone patients to 17.7 for patients with ACS, 
CADD, CVD, and PAD (N=1456). CONCLUSIONS: In elderly HRVD patients, classic 
cardiovascular risk factors are consistent and common, but are undertreated in 
the U.S.  
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OBJECTIVES: Less numbers of studies on cardiovascular diseases were found  
in Indian population. So, the results of present study may helpful in improving 
the consistency and quality of care in the management of AMI in Indian 
population. The objective of this retrospective observational study was to 
evaluate the physicians’ adherence to 2009 American Heart Association (AHA) 
/American College of Cardiology (ACC) guidelines in the management of AMI. 
METHODS: Chi-Square test and student t-test were used for analysing the data. 
The adherence to early and late performance measures was assessed by 
comparing the performance measures actually given to the patients on 
admission and discharge with those recommended by the AHA/ACC guidelines 
for management of AMI. RESULTS: A total of 127 patients’ with confirmed 
diagnosis of AMI were analysed in this observational study. Statistically 
significant difference was found between average ages of male and female 
patients (57.2±1.2, 66±1.7 respectively, P<0.05). The adherence to clinical 
performance measures like aspirin, antithrombin and thrombolytic therapy on 
admission and discharge was found to be 100%. Adequate AMI management was 
seen in 75.9% NSTEMI and 70.4% STEMI patients. No difference in the adequate 
management for AMI was found between STEMI and NSTEMI groups (P>0.05). 
Low adherence was seen for the prescription of b-blocker on discharge in both 
STEMI and NSTEMI patients (83.7%, 86.2% respectively) when compared to other 
performance measures. The adherence to all early performance measures in 
both the groups was found to be good. CONCLUSIONS: The overall adherence to 
early and late performance measures in AMI management in this North Indian 
study population was satisfactory. Adaptation and implementation of clinical 
practice guidelines in any health care sector will increase the consistency and 
quality of care. 
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OBJECTIVES: Atrial fibrillation (AF) commonly complicates acute coronary 
syndromes (ACS) and selecting antithrombotic regimen for these patients is 
complex. We describe the spectrum of antithrombotic use in a community 
cohort of patients with ACS, and identify predictors of the choice of strategies in 
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ACS patients with AF. METHODS: Olmsted County, Minnesota residents 
hospitalized with incident myocardial infarction or unstable angina during 2005-
2010 were identified and classified according to the presence or absence of AF 
either prior to or during the index ACS hospitalization. Logistic regression 
identified factors associated with double/triple versus none/single 
antithrombotic therapy in those with AF. RESULTS: Of 1108 incident ACS atients, 
229 (20.7%) had concomitant AF (ACS+AF). Only 15.7% ACS+AF patients 
underwent percutaneous interventions (PCI) in contrast to 35.4% ACS patients 
without AF having PCI. AF substantially impacted the choice of antithrombotic 
strategy at discharge. Nearly half (49.3%) of the ACS+AF patients were discharged 
on either two or three antithrombotic agents; 39.3% received aspirin only. One-
third (33.6%) of those with ACS+AF received warfarin, mostly in combination 
with a single antiplatelet, and 10.0% of patients received warfarin with two 
antiplatelet agents. In contrast, among ACS patients without AF, 63.5% were 
discharged on either two or three agents, the majority on dual antiplatelets, with 
only 3.8% on warfarin and 1.3% on warfarin with two antiplatelets. After 
adjustment for age and sex, the predictors of double/triple agent treatment 
strategies in ACS+AF patients included higher peak troponin, PCI on index 
admission, higher body mass index, non-smoking status, hypertension, and 
higher CHADS2score. CONCLUSIONS: In the community, AF frequently coexists 
with ACS. AF, in conjunction with patient-level risk factors, influences the choice 
of antithrombotic agents in ACS patients. These observational data underscore 
the importance of ACS+AF and the need for evidence from randomized trials and 
observational studies to guide clinical decisions. 
